Thermo Fisher Scientific Inc. Stock Performance
Thermo Fisher Scientific Inc. shares closed at $658.52, reflecting a daily decline of approximately 1.05%, per SID market data. Despite the session pullback, the stock has demonstrated notable momentum over intermediate time horizons, gaining 4.97% over the past month and 41.97% over the trailing three months. On a one-year basis, TMO has appreciated 14.39%, underperforming the broader market but reflecting steady recovery within the Healthcare sector. Technical indicators show the stock trading well above its 50-day moving average of $593.53 and its 200-day moving average of $528.06, suggesting sustained bullish positioning according to Massive/Polygon data. The 14-day RSI stands at 66.7, approaching but not yet breaching overbought territory. TMO carries a beta of 0.902, indicating slightly lower volatility relative to the broader market. Average daily trading volume is approximately 2.05 million shares, supporting adequate liquidity for institutional participation.
Thermo Fisher Scientific Inc. Valuation Analysis
Thermo Fisher Scientific currently commands a market capitalization of approximately $219.4 billion, positioning it among the largest companies in the Healthcare sector, per SID market data. The stock trades at a price-to-earnings ratio of 33.30, reflecting a premium valuation relative to broader market averages and suggesting the market is pricing in expectations of sustained earnings growth. However, the PEG ratio stands at an elevated 577.17, indicating that the current P/E multiple significantly exceeds the company's near-term earnings growth trajectory. According to SEC filings, the price-to-book ratio is 4.29, consistent with a capital-intensive life sciences tools business that carries significant goodwill from acquisitions. Thermo Fisher offers a modest dividend yield of approximately 0.29%, reflecting the company's preference for capital allocation toward acquisitions and share repurchases over direct shareholder returns. These valuation metrics collectively indicate the stock is priced for execution on long-term revenue and margin expansion targets.
Smart Money Activity for TMO
Thermo Fisher Scientific registers a composite smart money score of 54 out of 100, reflecting a neutral overall signal according to SID market data. Institutional ownership scores a perfect 25 out of 25, indicating maximum conviction among large asset managers and hedge funds per 13F institutional filings. In contrast, insider activity scores a modest 9.7 out of 25, driven by a notable imbalance between purchases and dispositions. According to SEC Form 4 filings, there have been 20 insider transactions over the past 90 days, comprising just 2 purchases against 18 sales, signaling that executives and directors have been net sellers during the stock's recent rally. Dark pool activity scores 8.5 out of 25, suggesting relatively muted off-exchange accumulation. Congressional trading interest registers at 11.2 out of 25, reflecting moderate legislative attention. The divergence between strong institutional positioning and persistent insider selling presents a mixed signal, with institutions maintaining high conviction while company insiders have elected to reduce personal exposure during the stock's three-month advance of nearly 42%.
Thermo Fisher Scientific Inc. Earnings Outlook
Thermo Fisher Scientific has delivered consecutive earnings beats in its two most recently reported quarters, according to company earnings reports. In the quarter reported on April 23, 2026, the company posted earnings per share of $5.44 against a consensus estimate of $5.23, representing a positive surprise of $0.21 or approximately 4.0%. The subsequent quarter reported on July 23, 2026 showed further acceleration, with actual EPS of $6.03 exceeding the estimate of $5.71 by $0.32, a surprise of roughly 5.6%. Looking ahead, analysts project EPS of $5.71 for the quarter with results expected on July 22, 2026, and $6.41 for the quarter scheduled for October 21, 2026, per analyst estimates. The upward trajectory in consensus expectations reflects improving demand fundamentals across Thermo Fisher's analytical instruments, specialty diagnostics, and laboratory products segments. The consistent pattern of outperformance suggests management has maintained conservative guidance practices.
Wall Street Analyst Ratings for TMO
Wall Street consensus on Thermo Fisher Scientific skews constructively, with the majority of recent coverage actions reflecting positive or neutral positioning, per Wall Street analyst reports. On September 3, 2026, CLSA initiated coverage with an Outperform rating, adding a new bullish voice to the coverage universe. Morgan Stanley maintained its Overweight rating on July 27, 2026, reaffirming confidence in the company's growth trajectory following quarterly results. On the same date, Piper Sandler reiterated a Neutral stance, representing a more measured view. Barclays maintained its Overweight rating on July 24, 2026, while RBC Capital held its Sector Perform rating on the same date, per SID consensus data. Among the five most recent analyst actions, three carry bullish or outperform-equivalent ratings, while two reflect neutral or market-perform positioning. No analyst has issued a negative or underperform rating in recent coverage, indicating that sell-side sentiment remains broadly supportive of Thermo Fisher's fundamental outlook and competitive positioning within the life sciences tools industry.
